Zydus gets China nod for Venlafaxine ER

has secured approval from China’s National Medical Products Administration (NMPA) to market Venlafaxine Extended-Release capsules in 75 mg and 150 mg strengths, marking the group’s first-ever regulatory approval in China, a key milestone for its global expansion plans . The product targets large and chronic mental health conditions and Major Depressive Disorder, Generalised Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder by helping rebalance serotonin and norepinephrine to improve mood and reduce anxiety, positioning Zydus to serve meaningful therapeutic demand in China’s central nervous system segment . Manufacturing will be done at the company’s Moraiya, Ahmedabad facility, suggesting supply readiness and potential operational leverage as Zydus enters a new, regulated market with a proven molecule and a differentiated extended-release formulation. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.